Capecitabine-related cardiotoxicity: recognition and management.
Saif
Muhammad Wasif
MW
Yale University School of Medicine, Section of Medical Oncology, New Haven, CT 06520, USA. wasif.saif@yale.edu
Tomita
Megumi
M
Ledbetter
Leslie
L
Diasio
Robert B
RB
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D000069287:Capecitabine; D003110:Colonic Neoplasms / Q000188:drug therapy; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011355:Prodrugs; D012004:Rectal Neoplasms / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil